Complimentary CEU:

Comparative Effectiveness of Therapies for Reducing the Risk of Primary Breast Cancer: Guidance for Shared Decision Making (Go to link under Monthly Complimentary CEU Tab)

In 2009, the Agency for Healthcare Research and Quality (AHRQ) published a systematic review on the comparative effectiveness and safety of tamoxifen, raloxifene, and tibolone for reducing the risk of primary breast cancer in women. 

Toward the goal of informed and shared decision making, this patient-centered educational program guides clinicians in discussing AHRQ's findings with women who may be candidates for FDA-approved therapies for reducing the risk of primary breast cancer.